LIDDS — Lidds AB Share News
0.000.00%
Last trade - 00:00- SEK3.36m
- SEK1.62m
Brief: Lidds Announces Data On Liproca Depot From Open Label Extension Study
Brief: LIDDS Licensee Evaluates Novel Expeditated Regulatory Path For Liproca Depot In China
Brief: Lidds Q2 Pre-Tax Loss Narrows To SEK 5.3 Million
Brief: Lidds Gets About SEK 59.3 Million Before Issue Expenses
Brief: Lidds Announces A Capital Raise
Brief: Lidds: Liproca Phase IIb Study Results Indicate Cancer Control
Brief: Lidds Announces Positive Meeting With The Swedish Medical Products Agency
Brief: LIDDS Q1 Pre-tax Loss Widens To SEK 8.0 Million
Brief: Lidds Says Analysis Of Tumors Confirms Depot Function Of NZ-Tlr9
Brief: Lidds Q4 Pre-Tax Loss Widens To SEK 15.1 Mln
Brief: Lidds Obtains Novel US Product Patent
Brief: Lidds Q3 Pre-Tax Result Turns To Loss Of SEK 2.8 Mln
Brief: Lidds Liproca Depot Phase IIb Study Results Presented At EMUC19 Showing Both Primary And Secondary Endpoints Being Met
Brief: Lidds Will Receive Proceeds Of SEK 9.0 Mln In Share Issue
Brief: Lidds Licensee Prepares For Phase III Trial In China
Brief: Lidds Licensee Jiangxi Puheng Pharma Prepares For Phase III Trial In China
Brief: Lidds Adds Lithuanian Clinics To Phase I Study
Brief: LIDDS: Liproca Depot Open Label Extension Study Indicates PSA Reduction For Up To One Year
Brief: Lidds Announces Preliminary Results From Phase IIb Liproca Depot Dose-finding Study